Cardiol Therapeutics Inc.

NASDAQ:CRDL

Drug Manufacturers - Specialty & Generic

Healthcare
$0.95 -0.47%

-$0.01 today

Market cap
$114.64M
Beta
0.80
P/E (TTM)
-4.5
EPS (TTM)
-$0.33
52W Low $0.88High $1.71

Volume 0.31M

Average 0.68M

CRDL Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Cardiol Therapeutics Inc.NASDAQ: CRDL

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses turns negative

Q1 FY2026 other income / expenses was -CA$1.11M, compared with CA$141.41K a year earlier. Trailing-twelve-month other income / expenses was -CA$758.66K. Over 3 fiscal years it compounded at -59.8% a year.

Context

  • Other income / expenses increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other income / expenses holds near -CA$1.11M or moves back toward the trailing-twelve-month quarterly average of -CA$189.66K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-CA$1.11M-236.2% QoQ
Last fiscal yearDec 2025
CA$497.42K-86.2% YoY
LTMMar 2026
-CA$758.66K-120.8% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-888.3%——
1 year-86.2%——
3-year CAGR-59.8%——
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

CAD · from the income statement

Latest · FY2025
497.42K CAD
Year-over-year change
-86.2%
4-year CAGR
-45.3%

Other Income / Expenses vs competitors

How CRDL compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -120.8% is the 9th highest of 10, against a peer median of -42.2%.
  • Over three fiscal years its annual growth of -59.8% compares with a peer median of +15.6%.
CRDL Competitors
Other Income / Expenses for CRDL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMAImageneBio IncLTM Mar 2026$10.53M USD+5.4%+8.8%—
KLRSKalaris Therapeutics IncLTM Mar 2026$3.53M USD+1344.0%——
CNTBConnect Biopharma Holdings LimitedFY2025$2.79M USD-60.4%+22.4%4360.9%
MBOTMicrobot Medical Inc.LTM Mar 2026$1.83M USD+210.7%+142.0%1742.9%
VANIVivani Medical, Inc.LTM Mar 2026$727K USD-42.2%-49.5%—
HYPRHyperfine, Inc.LTM Mar 2026-$38K USD-101.2%+28.6%0.2%
IFRXInflaRx N.V.LTM Mar 2026-€440.14K EUR-104.4%-1.4%1500.6%
CRDLCardiol Therapeutics Inc.LTM Mar 2026-CA$758.66K CAD-120.8%-59.8%—
ASRTAssertio Holdings, Inc.LTM Mar 2026-$12.7M USD-581.9%—12.4%
INCRInterCure Ltd.LTM Jun 2025-₪19.09M ILS+51.3%—7.9%
Peer median (excluding CRDL) —-42.2%+15.6%756.5%

Competitors are the stored peer set for CRDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue62.27K0000
Cost of Revenue174.26K162.23K187.38K00
Gross Profit(112K)(162.23K)(187.38K)00
Gross Margin-179.9%————
Research & Development8.59M13.99M10.73M14.01M14.02M
Selling, General & Admin21.86M16.34M11.55M25.89M20.2M
Operating Expenses30.46M30.33M22.29M40.28M34.32M
Depreciation & Amortization174.26K162.23K187.38K162.11K101.98K
EBITDA(24.84M)(22.66M)(21.04M)(36.52M)(33.72M)
EBITDA Margin-39891.0%————
Operating Income(30.57M)(30.49M)(22.47M)(40.28M)(34.32M)
Operating Margin-49092.4%————
Interest Income106K1.24M2.04M1.19M726.4K
Interest Expense00000
Other Income / Expenses5.56M7.68M1.25M3.6M497.42K
Income Before Tax(25.01M)(22.82M)(21.22M)(36.68M)(33.82M)
Pre-Tax Margin-40170.9%————
Income Tax Expense00000
Net Income(25.01M)(22.82M)(21.22M)(36.68M)(33.82M)
Net Margin-40170.9%————
EPS (Basic)(0.73)(0.49)(0.44)(0.51)(0.39)
EPS (Diluted)(0.73)(0.49)(0.44)(0.51)(0.39)
Weighted Avg Shares43.22M62.51M64.46M71.57M86.99M
Weighted Avg Shares (Diluted)43.22M62.51M64.46M71.57M86.99M

Cardiol Therapeutics Inc.

NASDAQ:CRDL

Intrinsic Alpha fair value

Locked

Current Price

$0.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.